all in Medical Technology

Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients

CHICAGO, June 15 /PRNewswire-USNewswire/ -- Vitamin D deficiency was found to be prevalent in cancer patients regardless of nutritional status, according to the results of a recent study conducted at Cancer Treatment Centers of America (CTCA). Based on these results, CTCA researchers determine...

AdvanDx Launches Fast, 90 Minutes Protocol for All CE-IVD Marked PNA FISH(R) Tests in Europe

Pathogen Identification Results in 90 Minutes Direct from Positive Blood Cultures Faster Results to Help Clinicians Improve Antibiotic Selection and Outcomes for Critical Infections WOBURN, Mass. and VEDBAEK, Denmark, April 28 /PRNewswire/ -- AdvanDx today announced that it has launched ...

AUA Guideline: Full Kidney Removal Not Necessary for All Kidney Tumors

Early-stage renal masses should be treated with nephron-sparing approaches when possible LINTHICUM, Md., April 27 /PRNewswire-USNewswire/ -- Radical nephrectomy (complete removal of the affected kidney) is not the best treatment for most small kidney tumors because it puts patients at risk fo...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

Data Being Presented Today at 44th Annual Meeting of EASL Management to Discuss Study Results and Program Status During Q1 Financial Results Call at 5 P.M. EDT Today SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced that ANA598,...

Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant

-Company Provides Update on Cash Position- -Biologics License Application for Wrinkles/Nasolabial Folds Indication Expected To Be Filed Within Two Weeks- EXTON, Pa., March 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE ) announced today positive top-line efficacy results ...

Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study

MUNICH, Germany, September 1 /PRNewswire-FirstCall/ -- Biosensors International Group, Ltd ("Biosensors", "Company"), (Bloomberg: BIG:SP), (Singapore:B20) today announced that a next-generation drug-eluting stent, developed by Biosensors, has demonstrated equal safety and efficacy as compared ...

Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant

Investor Conference Call to be held on Wednesday, August 6, 2008 at 8:00 a.m. EXTON, Pa., Aug. 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today positive top-line efficacy and safety results from two pivotal, Phase III clinical studies ...

Task Force Recommends Screening for Hearing Loss in All Newborns

ROCKVILLE, Md., July 3 /PRNewswire-USNewswire/ -- All newborn infants should be screened for congenital hearing loss that is present at birth, according to a new recommendation from the U.S. Preventive Services Task Force. The recommendation and the accompanying summary of evidence appear in t...

GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers

Data being made available on NCI Database Could Save Drug Development Time and Capital for Other Research Institutions PHILADELPHIA, June 20 /PRNewswire-FirstCall/ -- Marking another positive step in the collaborative fight against cancer, GlaxoSmithKline (NYSE: GSK ) announced to...

Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders

New Data to be Presented at ASCO Shows Survival Benefit in Complete and Partial Responders Compared with Chemotherapy Alone BERKELEY HEIGHTS, N.J., May 29 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced the results of long-term followup from a Phase 3...

Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration

First Presentation of Full Data Set from the TRIUMPH-1 Trial of Inhaled Treprostinil SILVER SPRING, Md., May 21 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR ) and its wholly-owned subsidiary Lung Rx, Inc. today announced that data from s...

Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose

WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investiga...

Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients

SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that it has ceased all negotiations with potential partners for its inhaled insulin programs as a result of new data analysis from ongoing clinical trials conducted by Pfizer Inc. A...

U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims

NEW YORK, Jan. 23 /PRNewswire-USNewswire/ -- The Public Patent Foundation ("PUBPAT") announced today that the U.S. Patent & Trademark Office has rejected four key HIV/AIDS drug patents held by Gilead Sciences that relate to the drug known generically as tenofovir disoproxil fumarate (TDF), a k...

Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes

BOSTON, Dec. 19 /PRNewswire-USNewswire/ --- When cholesterol-clogged plaque narrows an artery that feeds the heart, the body responds by trying to bulk up tiny blood vessels in the heart. As these so-called collateral vessels grow more muscular and interconnected, they begin to reroute some of...

Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis

Findings reinforce the benefits of Asacol for ulcerative colitis patients AVENTURA, Fla., Dec. 5 /PRNewswire/ -- Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an eff...

Lack of Medicare Part D Coverage for All Medically Necessary Prescriptions Endangers Older Americans and Those with Chronic Diseases and Disabilities

Coalition of Patient and Consumer Groups calls for Legislative Action to Ensure Access to 'Off-Label' Drug Treatments WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Twenty-six patient, family caregiver and health professional organizations are calling upon Congress to pass legisla...

Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia

- Trial CL-05 Results Showed Cethromycin had 94.0% Clinical Cure Rate Compared to 93.8% Clinical Cure Rate for Biaxin(R), a Current Standard of Care Treatment - - Trial CL-05 and Trial CL-06 to Form the Core of New Drug Application - CHICAGO, Nov. 15 /PRNewswire-...

Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos

New technology developed by researchers at Reproductive Medicine Associates of New Jersey awarded General Program Prize Paper at American Society for Reproductive Medicine Annual Meeting WASHINGTON and MORRISTOWN, N.J., Oct. 18 /PRNewswire/ -- Researchers at Reproductive Medici...

Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints

- Millennium on track to file sNDA in first quarter 2008 - CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced that the interim analysis results of the large, international Phase III VISTA(1) trial in patients with newly...

Acuity One-Year Findings Meet All Primary Endpoints in Favor of Angiomax (Bivalirudin) Alone Treatment Group

Major Bleeding in Patients Treated for Acute Coronary Syndromes (ACS) Nearly Triples the Risk of Death at One Year NEW ORLEANS, March 26, 2007 /PRNewswire/ -- One-year findings from the landmark ACUITY trial show that acute coronary syndrome (ACS) patients in the "Angiomax(R) (bivalirudin) alone" ...

Hematology Analyzers Simple, Sophisticated Technology Serving All Patients

Betsy Donnelly, MT (ASCP) Contributing Editor Some form of electronic hematology analyzer is found at the center of most clinical laboratories. A blood cell count is usually the first screening test used to assess general health, rule out anemia or infection, and monitor cancer patients ...

Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal

Kerri Penno Contributing Editor Medical conventions are challenged every day. Already in the new year, the effectiveness of cold medicine and the gold standard in breast cancer treatment have been challenged. Standards in cholesterol testing are the latest casualty of medical innovation....

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

...ice represents a paradigm shift in the way physicians will deliver drugs to all organ systems in the future. "The implantation of this kind of devic...center known for its family friendly environment of children afflicted with all forms of eye disease and provides a full range of inpatient and outpatient ...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...eliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. all statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues,...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...inued operations. Accordingly, Isis has presented all periods of Ibis' operating results in Isis' financ...e. FSP 14-1 required retrospective application to all periods presented. Accordingly, the amount of int...reatment with mipomersen versus 3% for placebo and all of its secondary endpoints in a highly statistical...

Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors

...ose rate brachytherapy treatment, HDR therapy can be delivered on an outpatient basis at Cancer Centers of North Carolina's office, which incorporates all patient needs in one central location. In addition, treatment times for HDR brachytherapy are typically 10-15 minutes in duration instead of several ...

SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite

...DC) and Thesaurus Management System 4.6 (TMS). SIRO plans to roll out the OLSAS to its European operations soon to have the system working in all geographies in which the company has operations. About SIRO SIRO Clinpharm Private Limited (SIRO) is among one of the leading global Cli...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

... subsequent additional six-month treatment period. Patients were on average 65 years old (54-84) and had an average lumbar spine BMD T-score of -2.93. all patients underwent four weeks of pretreatment with standard regional supplementation requirements for osteoporosis of not less than 400 IU per day of ...

NewCardio Announces Master Services Agreement With Dedicated Phase I

...ement (MSA) with NewCardio. Under terms of this agreement, Dedicated Phase I will receive a license to use NewCardio's QTinno(TM) software solution in all TQT studies where fully automated readings are obtained. It is anticipated that Dedicated Phase I, by utilizing QTinno(TM) in addition to its e...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

...f the group administered Labopharm's trazodone. In addition, patients on Labopharm's trazodone demonstrated significant improvements versus placebo in all three quality of sleep end points, with an improvement by the first week of therapy in "overall quality of sleep" and "awakening during the night". Th...

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

... employing proprietary, novel production technology which is not dependent on growing influenza virus in eggs. Chicken eggs are used to produce almost all of the world's influenza vaccine supply. In addition, Novavax has produced essential reagents for measuring vaccine potency. The Company also has pl...

2,500 Cases Completed With the Magnetic Irrigated Catheter

...ations of a wide variety of cardiac arrhythmias in all four chambers of the heart and across a broad spec...e magnetic navigation technology as a platform for all manner of cardiac and vascular interventions," sai...d other commitments in any particular period or at all because some of these purchase orders and other co...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...in collaboration partnerships on attractive commercial terms, or that cover all major markets, our business, results of operations and financial condition ... the audited financial statements at that date but does not include all of the information and notes required by generally accepted account...

DNA Helps Reunite Children With Their Families

...ion of missing persons and human remains. Eisenberg and Lorente hope all countries throughout the world will develop national databases that will li... criminals from kidnapping and trafficking children, the most vulnerable of all victims. About the University of North Texas Health S...

ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer

...tion-detection testing in colon-cancer patients which can identify nearly all of the patients who will not benefit from taking either Vectibix or Erbitux...he United States offer this test, ARUP Laboratories' KRAS assay detects all 12 mutations at codons 12 and 13; another highly publicized assay on the ma...

CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research

...M operates by inviting, assessing and funding multidisciplinary projects that involve active participation by Netherlands-based academia and industry. all CTMM projects are judged by an independent International Scientific Advisory Committee and approved by a Supervisory Board based on their significant ...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

..., the products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... of a bone, radiation to bone, surgery to bone, or spinal cord compression. all are serious complications for advanced cancer patients. Regardless o...that could cause actual results to differ materially from those described. all statements, other than statements of historical fact, are statements that c...

Project Zero Delay Accelerates Drug's Path to Clinical Trial

... will someday offer new benefits to cancer patients." Co-authors with Kurzrock and Bast are: Susan Pilat, Marcel Bartolazzi, and Dwana Sanders, all of M. D. Anderson's Department of Investigational Therapeutics; Stanley Tucker, Ph.D., Office of Translational Research. From AstraZeneca: Jill Hood, ...